Cutaneous Adverse Drug Reactions

皮肤药物不良反应

• 批准号: 7965853
• 负责人: Heidi Kong
• 金额: $ 4.21万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7965853
• 关键词: Adverse effects; Appearance; BAY 54-9085; Biopsy; Classification; Clinic; Clinical; Clinical Trials; Collaborations; Consult; Cutaneous; Data; Dermatologic; Dermatologist; Dermatology; Diagnosis; Dose; Drug toxicity; Evaluation; Goals; Hand; Knowledge; Life; Mediating; Medical; National Cancer Institute; Oncologist; Pain; Palmar-plantar erythrodysesthesia syndrome; Pathogenesis; Patients; Pharmaceutical Preparations; Photography; Protocols documentation; Publishing; Reaction; Recording of previous events; Research; Risk Factors; Skin; Therapeutic; Time; United States National Institutes of Health; base; experience; foot; improved; medical specialties; novel; oncology; research clinical testing

In fiscal year 2009, we published the data on hand-foot skin reaction related to sorafenib therapy from three NCI intramural trials to better understand the potential risk factors and possible pathogenesis of this painful treatment-limiting cutaneous adverse effect. This research required multi-specialty collaboration among dermatologists, oncologists, pharmacologists and statisticians. Patients on other investigational therapeutics are being systematically evaluated dermatologically at baseline and while on treatment. In addition to thorough clinical evaluations, subjects may undergo skin biopsies and medical photography.

在2009财年，我们公布了与以下相关的手足皮肤反应数据： 来自三项NCI内部试验的索拉非尼治疗，以更好地了解潜在风险 这种疼痛的治疗限制性皮肤不良反应的因素和可能的发病机制。 这项研究需要皮肤科医生，肿瘤科医生， 药理学家和统计学家。正在接受其他试验性治疗的患者 在基线和治疗期间进行皮肤病学系统评价。除了 通过临床评估，受试者可能会接受皮肤活检和医学摄影。